120 related articles for article (PubMed ID: 28639200)
21. Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy.
Xia W; Li D; Wang G; Ni J; Zhuang J; Ha M; Wang J; Ye Y
Cancer Gene Ther; 2016 Oct; 23(10):333-340. PubMed ID: 27608773
[TBL] [Abstract][Full Text] [Related]
22. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
24. Suppression of Prostate Cancer Metastasis by DPYSL3-Targeted saRNA.
Li B; Li C
Adv Exp Med Biol; 2017; 983():207-216. PubMed ID: 28639202
[TBL] [Abstract][Full Text] [Related]
25. Developing small activating RNA as a therapeutic: current challenges and promises.
Kwok A; Raulf N; Habib N
Ther Deliv; 2019 Mar; 10(3):151-164. PubMed ID: 30909853
[TBL] [Abstract][Full Text] [Related]
26. Development of Therapeutic dsP21-322 for Cancer Treatment.
Kang MR; Li G; Pan T; Xing JC; Li LC
Adv Exp Med Biol; 2017; 983():217-229. PubMed ID: 28639203
[TBL] [Abstract][Full Text] [Related]
27. RNA Activation-A Novel Approach to Therapeutically Upregulate Gene Transcription.
Tan CP; Sinigaglia L; Gomez V; Nicholls J; Habib NA
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770939
[TBL] [Abstract][Full Text] [Related]
28. Down-regulated expression of the CCAAT/enhancer binding protein alpha and beta genes in human hepatocellular carcinoma: a possible prognostic marker.
Tomizawa M; Watanabe K; Saisho H; Nakagawara A; Tagawa M
Anticancer Res; 2003; 23(1A):351-4. PubMed ID: 12680236
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Potential of Small Activating RNAs (saRNAs) in Human Cancers.
Yoon S; Rossi JJ
Curr Pharm Biotechnol; 2018; 19(8):604-610. PubMed ID: 29804529
[TBL] [Abstract][Full Text] [Related]
30. Tackling Tumors with Small RNAs Derived from Transfer RNA.
Slack FJ
N Engl J Med; 2018 May; 378(19):1842-1843. PubMed ID: 29742367
[No Abstract] [Full Text] [Related]
31. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma.
Xu L; Hui L; Wang S; Gong J; Jin Y; Wang Y; Ji Y; Wu X; Han Z; Hu G
Cancer Res; 2001 Apr; 61(7):3176-81. PubMed ID: 11306505
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.
Kudo M
Oncology; 2008; 75 Suppl 1():1-12. PubMed ID: 19092266
[TBL] [Abstract][Full Text] [Related]
33. C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia.
Hughes JM; Legnini I; Salvatori B; Masciarelli S; Marchioni M; Fazi F; Morlando M; Bozzoni I; Fatica A
Oncotarget; 2015 Jul; 6(21):18534-44. PubMed ID: 26053097
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for hepatocellular carcinoma.
Li S; Yang F; Ren X
Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
[TBL] [Abstract][Full Text] [Related]
35. Treatment options for hepatocellular carcinoma.
Sandhu DS; Tharayil VS; Lai JP; Roberts LR
Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):81-92. PubMed ID: 19072372
[TBL] [Abstract][Full Text] [Related]
36. A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood.
Lourenço AR; Coffer PJ
Oncogene; 2017 Sep; 36(37):5221-5230. PubMed ID: 28504718
[TBL] [Abstract][Full Text] [Related]
37. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
[TBL] [Abstract][Full Text] [Related]
38. New possibilities in hepatocellular carcinoma treatment.
Rasool M; Rashid S; Arooj M; Ansari SA; Khan KM; Malik A; Naseer MI; Zahid S; Manan A; Asif M; Razzaq Z; Ashraf S; Qazi MH; Iqbal Z; Gan SH; Kamal MA; Sheikh IA
Anticancer Res; 2014 Apr; 34(4):1563-71. PubMed ID: 24692683
[TBL] [Abstract][Full Text] [Related]
39. C/EBPα mediates the maturation and antitumor functions of macrophages in human hepatocellular carcinoma.
Wang Y; Li Z; Chen W; Wang J; Huang Z; Yu XJ; Zhang YJ; Zheng L; Xu J
Cancer Lett; 2024 Mar; 585():216638. PubMed ID: 38266805
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia regulates the expression and localization of CCAAT/enhancer binding protein α by hypoxia inducible factor-1α in bladder transitional carcinoma cells.
Xue M; Li X; Chen W
Mol Med Rep; 2015 Aug; 12(2):2121-7. PubMed ID: 25824695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
